Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Cerilliant
Boehringer Ingelheim
Farmers Insurance
Merck
McKinsey
Mallinckrodt
Queensland Health
AstraZeneca
Healthtrust

Generated: January 18, 2018

DrugPatentWatch Database Preview

Oritavancin diphosphate - Generic Drug Details

« Back to Dashboard

What are the generic sources for oritavancin diphosphate and what is the scope of oritavancin diphosphate freedom to operate?

Oritavancin diphosphate
is the generic ingredient in one branded drug marketed by The Medicines Co and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oritavancin diphosphate has one hundred and thirty-eight patent family members in thirty-seven countries.

One supplier is listed for this compound.
Summary for oritavancin diphosphate
International Patents:138
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 8
Clinical Trials: 141
Patent Applications: 7
Drug Prices:see low prices
DailyMed Link:oritavancin diphosphate at DailyMed

US Patents and Regulatory Information for oritavancin diphosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
The Medicines Co ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
The Medicines Co ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
The Medicines Co ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
The Medicines Co ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
The Medicines Co ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
The Medicines Co ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
The Medicines Co ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for oritavancin diphosphate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
The Medicines Co ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 ➤ Subscribe ➤ Subscribe
The Medicines Co ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for oritavancin diphosphate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,952,466 Reductive alkylation of glycopeptide antibiotics ➤ Subscribe
5,843,889 Glycopeptide antibiotic derivatives ➤ Subscribe
5,977,062 Glycopeptide antibiotic derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for oritavancin diphosphate

Supplementary Protection Certificates for oritavancin diphosphate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2016 Austria ➤ Subscribe PRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323
2016000075 Germany ➤ Subscribe PRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319
0834 Netherlands ➤ Subscribe PRODUCT NAME: ORITAVANCIN; REGISTRATION NO/DATE: EU/1/15/989 20150323
2016 00044 Denmark ➤ Subscribe PRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323
90041-7 Sweden ➤ Subscribe PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Fish and Richardson
Novartis
Farmers Insurance
Colorcon
Chinese Patent Office
Covington
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot